This episode focuses on key updates in multiple sclerosis (MS) research from the 11th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. We begin with key trial updates, including the FENtrepid (NCT04544449) and MoonStone (NCT06564311) results presented by Amit Bar-Or, MD, FRCPC, University of Pennsylvania, Philadelphia, PA. Le Hanh Hua, MD, Cleveland Clinic, Las Vegas, NV, then discusses a secondary analysis of the OLIKOS study (NCT04486716), and Jeffrey Cohen, MD, Cleveland Clinic, Cleveland, OH, introduces the use of hematopoietic stem cell transplantation.

Novel technologies are discussed by Gianmarco Bellucci, MD, PhD, University of California, San Francisco, CA, Raphael Schneider, MD, PhD, FRCPC, CIP, St. Michael’s Hospital, Toronto, Canada, and Valentina Fossati, PhD, The Jackson Laboratory. Finally, Gary Cutter, MS, PhD, UAB School of Public Health, Birmingham, AL, shares the limitations of using brain atrophy measured by MRI as a clinical trial endpoint, and Dalia Rotstein, MD, University of Toronto, Toronto, Canada, discusses a study that found that MS onset precedes EBV infection in some cases.